- Open Access
Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a model
Immunity & Ageing volume 6, Article number: 4 (2009)
Hutchinson-Gilford progeria syndrome (HGPS) is a rare premature aging disorder that belongs to a group of conditions called laminopathies which affect nuclear lamins. Mutations in two genes, LMNA and ZMPSTE24, have been found in patients with HGPS. The p.G608G LMNA mutation is the most commonly reported mutation. The aim of this work was to compile a comprehensive literature review of the clinical features and genetic mutations and mechanisms of this syndrome as a contribution to health care workers. This review shows the necessity of a more detailed clinical identification of Hutchinson-Gilford progeria syndrome and the need for more studies on the pharmacologic and pharmacogenomic approach to this syndrome.
Biological ageing considers that some ageing-associated changes are programmed while others are stochastic and unpredictable [1, 2]. An alternative to the analysis of aging is the study of human genetic syndromes whose phenotypes show specific characteristics of human ageing. Premature ageing syndromes (or progeroid syndromes) constitute one of these alternatives since they are considered to be segmental progeroid syndromes .
Hutchinson-Gilford progeria syndrome (HGPS)
Hutchinson-Gilford progeria syndrome (HGPS; OMIM #176670) is a very rare genetic disease, characterized by precocious ageing in early infancy, with several clinical characteristics such as growth retardation after birth, failure to thrive and skin abnormalities (sclerotic skin dimpling and mottling), sleeping with eyes open, circumoral cyanosis, prominent eyes and cutaneous/scalp vasculature, decreased joint range of motion, micrognathia, premature atherosclerosis, loss of subcutaneous fat, alopecia, fingertip tufting, distal-joint abnormalities, altered pigmentation and generalized anomaly in bone development with pathogenic fracture and osteolysis [4–7].
The syndrome name is derived from the Greek word geras, meaning "prematurely old." It was first described by Jonathan Hutchinson in 1886, and named by Hastings Gilford in 1904. Since its first description in 1886, over 150 cases have been reported in the world [5, 8]. These patients have a short life expectancy with death occurring in adolescence, most times due to cardiovascular diseases .
There are other forms of progeria that manifest at several ages and are characterized by signs of ageing, such as the following syndromes: Wiedemann-Rautenstrauch, Cockayne, Werner, Emery-Dreifuss, Rothmund-Thomson, and Seckel .
The incidence of classic progeria has been estimated to be 1 per 4–8 million live births . Prevalence of sex has not been evidenced so far. The majority of HGPS patients are Caucasian [4, 5, 10]. Over 150 cases have been reported in the literature throughout the world . The average life expectancy for a patient with HGPS is 13 years, with an age range of 7 to 27 years old. Caucasians represent 97% of patients with HGPS, and cardiovascular abnormalities account for 75% of death in patients with the syndrome .
The objective of this present work was to carry out a literature review of the molecular traits and clinical features of Hutchinson-Gilford progeria syndrome (HGPS), in a search based on mutations in the genes involved with this genetic disease.
The keywords used for this review were progeria, ageing, LMNA gene and Hutchinson-Gilford. The search was performed using the international bibliographic databases and was started in the 1990s and updated to 2008.
Molecular mechanism of laminopathies
HGPS belongs to a group of disorders called laminopathies which affect nuclear lamins and include several phenotypes (figure 1). Mutations in the gene LMNA have been identified in the majority of cases of HGPS. The gene LMNA encodes nuclear lamin A, with the predominant somatic cell isoforms lamin A and C arising by alternative RNA splicing, which underlies and organizes the inner surface of the nuclear envelope [12–14]. There are at least 11 distinct diseases associated with >300 different mutations in LMNA [15–17]. Mutations in LMNA have been detected in 88% of patients with HGPS, while the genetic mechanism of the remaining 12% is still unknown .
Lamins are structural components of the nuclear lamina, a proteinaceous network underlying the inner nuclear membrane which determines the shape, integrity and size of the nucleus. Furthermore, lamin plays an important role in the organization of the pore complex, and recruits other proteins such as emerin for the nuclear envelope (figure 2). Lamins A and C are important for nuclear stability, play a role in transcription regulation in response to a chemical or mechanical stimulus, and are members of the intermediate-type filament proteins which also form part of the nuclear matrix scaffold [15, 16]. Due the multiple interactions between chromatin and the nuclear matrix, mutations in lamins A and C are thought to impair various nuclear functions including chromatin and chromosome stability, telomere integrity, regulation of transcription, DNA replication, cell cycle control and cellular differentiation, causing a variety of disorders which first affect striated muscle, adipocytes and peripheral nerves or cause the appearance of premature aging diseases called laminopathies. A single mutation in lamin A is the cause of HGPS [3, 18, 19].
Lamin A in mammals is an element of the polypeptide family of lamins. Its main components are lamins A, B1, B2 and C, with molecular weight ranging from 60,000 to 78,000. Lamins A and C are formed by the splicing of lamin A mRNA. Lamins B1 and B2 are coded by separate genes, while lamins A and C are identical in the first 566 amino acids. Lamin A is normally synthesized as a precursor molecule (prelamin A). Alternative splicing in exon 11 causes an increase in two different mRNAs which code for prelamin A and lamin C. Prelamin A, with 664 amino acids, has 98 carboxyl-terminal amino acids, while lamin C has 6 carboxyl-terminal amino acids. As lamin A contains a carboxyl-terminal CAAX box (C is cysteine, A is an aliphatic amino acid and X is any amino acid), it is modified by farnesylation, which does not occur in lamin C. Following farnesylation, the cleavage of the three last amino acids, and methylation of the carboxyl-terminal, an internal proteolytic cleavage takes place removing the last 15 coding amino acids, in order to generate a mature lamin A with 646 amino. Progerin, the altered product in HGPS, is an incompletely processed lamin A/C that remains farnesylated, leading to apparent loss of mechanical properties of the nuclear envelope and nuclear matrix. Cells expressing progerin may experience delayed mitotic progression which would be consistent with the early onset and global growth deficit of the HGPS phenotype .
The mutation G608G of HGPS and the consequent abnormal splicing produce a prelamin A that still retains the CAAX box, but is missing a part for endoproteolytic cleavage. Immunofluorescence of HGPS fibroblasts with lamin A antibodies revealed that 40–50% of the cells displayed a visible abnormality, an abnormal nuclear envelope morphology. Thus, this mutation in HGPS seems to act as a dominant-negative mutation that affects nuclear morphology .
Affected nuclear mechanisms and secondary alterations in gene expression may cause damage to the striated muscle of individuals with certain mutations in lamin A/C. Different mutations in lamins A and C may cause various tissue-specific pathological phenotypes . There are several reports about the nuclear abnormalities such as lobulation or "blebbing" of the nuclear envelope, increased nuclear surface area, thickening of the nuclear lamina, loss of peripheral heterochromatin and clustering of nuclear pore complexes [6, 22].
HGPS is related to a mutation in the LMNA gene or in ZMPSTE2 that codes for a metalloproteinase specifically involved in the post-translational proteolytic processing of prelamin A to mature lamin A, which is responsible for scaffolding and organizing the nuclear envelope surface (figure 3) [12, 23–25].
The inheritance pattern in progeria syndrome is autosomal dominant (or less frequently recessive when involving the ZMPSTE24 gene) [22, 26]. All subjects with HGPS have the disease as result of a de novo mutation (the most common mutation is p.G608G), as their parents are not affected. This mutation causes aberrant splicing in exon 11 and the deletion of 50 residues close to the C terminus of lamin A, including the second ZMPSTE24 cleavage site. This deletion prevents complete processing of prelamin A, resulting in the accumulation of a farnesylated lamin A, known as progerin. Five other different de novo dominant LMNA mutations have been found less frequently: p.E145K, p.S143F, p.R644C, p. T10I and p.E578V . Despite being very rare, mutations in HGPS are thought to have a paternal origin .
Patients with HGPS are infants who are healthy at birth and in the course of 1–2 years present signs of progressive premature ageing. Initially, sclerodermatous plaques appear on the skin of the hip and in the upper region of the lower extremities. These areas grow more and put virtually the entire body at risk, except for the genitals and some regions of the lower limbs. The production of sweat is simultaneously decreased and alopecia becomes evident. Some late signs are hyperpigmentation in sun-exposed areas, as well as dystrophic nails . The clinical manifestations of classic progeria include abnormalities in growth, skin and skeletal and cardiovascular systems, which are always present after the age of 3 years .
The ever present clinical features are prominent scalp veins, alopecia, bird-like facies, prominent eyes, abnormal dentition and delayed tooth eruption, micrognathia, short clavicles, horseman stance, pyriform thorax, thin legs with prominent joints, short stature and low weight for height, incomplete sexual maturation and lack of subcutaneous fat. The clinical manifestations that may be apparent or not are sclerodermatous skin, generalized alopecia, eyelashes and eyebrow alopecia, protruding ears with absent lobes, beaked nose, thin lips with centrofacial cyanosis, protracted anterior fontanel and high-pitched voice [4, 7, 10].
Patients who have most of the aforementioned characteristics are considered to have a classic case of progeria. However, individuals who have characteristics more or less intense of the syndrome are considered patients with atypical progeria .
The diagnostic methods of HGPS are clinical (serum lipid levels, hyaluronic acid excretion, blood count), histological (biopsies from areas of abdominal skin with abnormal nuclear morphology), radiological (abnormality found in the brain, thorax, long bones and phalanges) and by screening for mutations in the gene LMNA [12–14].
No laboratory offers a specific molecular genetic testing for prenatal diagnosis of progeria. Nevertheless, prenatal testing may be offered to families in which the causative mutation of the disorder has been identified in a family member .
Some clinical tests for confirmatory diagnosis are sequential analysis of the gene LMNA, which reveals point mutations in approximately 90% of the patients with HGPS, and the test for uniparental disomy of chromosome 1 and deletions associated with HGPS. Imaging studies may also be performed. Radiography detects manifestations that usually occur in the skull, thorax, long bones, and phalanges .
Under light microscopy, histological tests using skin biopsies from HGPS patients exhibit irregular nuclear envelope outlines, indicating the massive and global alterations of chromatin functions, including alterations of gene expression . Tests using keratinocytes from transgenic mice expressing progerin revealed alterations in nuclear shape such as decreased nuclear circularity, resulting in greater nuclear surface area and greater morphological diversity, thereby, microscopic analysis of the nuclear shape could be an interesting diagnostic alternative to be studied .
There is no known cure for progeria. Nonetheless, there are treatments in order to improve the clinical conditions. Regular diets may be prescribed, as well as routine immunizations, inspection for cardiovascular diseases, treatment with aspirin, surgical procedures, and physical and psychological therapies. Children with HGPS must have a regular diet. Common mulltivitamin tablets are appropriately given in normal doses. Supplements with fluoride are recommended, since there are dental problems. It is advised to occasionally give small doses of aspirin to children with HGPS, aimed at reducing the occurrence of heart attack and strokes. Atherosclerosis of the coronary artery may be diagnosed with an echocardiogram (ECG), and nitroglycerin may be useful should there be development of angina. The drug doses must be based on weight and the anesthetics must be used cautiously. As these children are susceptible to fractures, they should be routinely accompanied. Due to the susceptibility to dislocation of the hip bone because of coxa valga, conservative care and surgical procedures are recommended. In relation to delay or loss of the first dentition, dental extraction may be recommended. Physical and psychological therapies are recommended to help maintain the joints with good movement amplitude, as well as to foster social interaction, respectively .
Another therapeutic approach involves the use of farnesyltransferase inhibitors which have been shown to reverse abnormalities in nuclear morphology in cells expressing progerin . In vitro studies in fibroblasts have shown the capacity of farnesyltransferase inhibitors (FTI) to reverse nuclear alterations [28–30].
Using transgenic mice expressing progerin, an ammelioration and reversion of cardiovascular phenotype, number reduction of the spontaneious rib fractures and improved survival and growth was observed, indicating that these compounds are an interesting pharmacological alternative for future treatment of HGPS and progeroid syndromes, as well as anti-aging [14, 31, 32]. The promising results with FTIs led to an open-label clinical trial of the FTI use in HGPS (ClinicalTrials.gov number NCT000425607) .
Other possibilities of treatments studied involves the use of low levels of growth hormone, but hormonal replacement has had unsatisfactory effects in these patients [10, 11]. The use RNAi or antisense strategies might be useful for reduce the progerin production in HGPS patients, but this strategy have few studies [31, 33, 34]. The combined use of a statin and a biphosphonate, compounds that act in the same mevalonate pathway as FTIs, but the effect of these drugs alone and combined to treat HGPS remains an open question .
The causes of morbidity in HGPS are difficulty in development, cerebrovascular events, vertigo, migraine, necrosis of the head of the femur and luxation of the hip .
Despite all medical and technological advances in cardiovascular surgeries (catheterization, cardiac pacemaking), improvement in patients' life expectancy has not been achieved, due to their tendency to accumulate atheromatous plaques again. The main cause of death (in 75% cases) is cardiac or cerebrovascular abnormalities which include myocardial infarction and congestive heart failure due to premature atherosclerosis . Psychological support in these patients is important, as well as a good family circle, since there is no mental abnormality. However, they do have deficient body and physiopathologic control .
While there is a move towards precise molecular classification of "laminopathies" rather than the broad clinical categories in use to date, it appears essential that clinical features be documented in detail. This may help in answering parents' questions about prognosis. It may also contribute to a better understanding of the functions of lamin A, and may in the future help in determining the efficacy of pharmacogenetic interventions for Hutchinson-Gilford syndrome and other progeroid syndromes. Due the fact of the cencentration of progering is enhanced in fibroblast of older persons, HGPS and possibly other laminopathies may serve as a model for the normal ageing process.
Rattan SI: Theories of biological aging: genes, proteins, and free radicals. Free Radic Res. 2006, 40: 1230-1238. 10.1080/10715760600911303.
Irminger-Finger I: Science of cancer and aging. J Clin Oncol. 2007, 25: 1844-1851. 10.1200/JCO.2007.10.8928.
Arboleda G, Ramírez N, Arboleda H: The neonatal progeroid syndrome (Wiedemann-Rautenstrauch): a model for the study of human aging?. Exp Gerontol. 2007, 42: 939-943. 10.1016/j.exger.2007.07.004.
Sarkar PK, Shinton RA: Hutchinson-Guilford Progeria syndrome. Postgrad Med J. 2001, 77: 312-317. 10.1136/pmj.77.907.312.
Pardo RAV, Castillo ST: Progeria. Rev Chil Pediatr. 2002, 73: 5-8.
De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Merrer ML, Lévy N: Lamin A Truncation in Hutchinson-Gilford Progeria. Science. 2003, 300: 2055-10.1126/science.1084125.
Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith ACM, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO, Gahl WA, Introne WJ: Phenotype and course of Hutchinson-Gilford Progeria Syndrome. N Eng J Med. 2008, 358: 592-604. 10.1056/NEJMoa0706898.
Engels WR, Johnson-Schlitz D, Flores C, White L, Preston CR: A Third Link Connecting Aging with Double Strand Break Repair. Cell Cycle. 2007, 6: 131-135.
Capell BC, Collins FS: Human laminopathies: nuclei gone genetically awry. Nature Rev Gen. 2006, 7: 940-952. 10.1038/nrg1906.
Shah KN, Kaiser HW: Hanfland J Hutchinson-Gilford Progeria e Medicine. Instant access to the mind of medicine. 2008, http://www.emedicine.com/derm/topic731.htm
De Paula Rodrigues GH, Tâmega IE, Duque G, Dias Neto VS: Severe bone changes in a case of Hutchinson-Gilford syndrome. Ann Genet. 2002, 45: 151-155.
Faivre L, Cormier-Daire V: Progeria. Orphanet encyclopedia. http://www.orpha.net/data/patho/GB/uk-progeria.pdf
Mazereeuw-Hautier J, Wilson LC, Mohammed S, Smallwood D, Shackleton S, Atherton DJ, Harper JI: Hutchinson-Gilford progeria syndrome: clinical findings in three patients carrying the G608G mutation in LMNA and review of the literature. Br J Dermatol. 2007, 156: 1308-1314. 10.1111/j.1365-2133.2007.07897.x.
Wang Y, Panteleyev AA, Owens DM, Djabali K, Stewart CL, Worman HJ: Epidermal Expression of the Truncated Prelamin A Causing Hutchinson-Gilford Progeria Syndrome: Effects on Keratinocytes, Hair and Skin. Hum Mol Genet. 2008, 17: 2357-2369. 10.1093/hmg/ddn136.
Lammerding J, Schulze PC, Takahashi T, Kozlov S, Sullivan T, Kamm RD, Stewart CL, Lee RT: Lamin A/C deficiency cause defective nuclear mechanics and mechanotransduction. J Clin Invest. 2004, 113 (3): 370-378.
Neveling K, Bechtold A, Hoehn H: Genetic instability syndromes with progeroid features. Z Gerontol Geriatr. 2007, 40: 339-348. 10.1007/s00391-007-0483-x.
Dechat T, Pfleghaar K, Sengupta K, Shimi T, Shumaker TK, Solimando L, Goldman RD: Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008, 22: 832-853. 10.1101/gad.1652708.
Kudlow BA, Kennedy BK, Monnat RJ: Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol. 2007, 8: 394-404. 10.1038/nrm2161.
Worman HJ, Courvalin JC: How do mutations in lamins A and C cause disease?. J Clin Invest. 2004, 113: 349-351.
Scaffidi P, Misteli T: Lamin Adependent nuclear defects in human aging. Science. 2006, 312: 1059-1063. 10.1126/science.1127168.
Gordon LB, Harten IA, Calabro A, Sugumaran G, Csoka AB, Brown WT, Hascall V, Toole BP: Hyaluronan is not elevated in urine or serum in Hutchinson-Gilford Progeria Syndrome. Hum Genet. 2003, 113: 178-187.
Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS: Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature. 2003, 423: 293-298. 10.1038/nature01629.
Kilic F, Johnson DA, Sinensky M: Subcellular localization and partial purification of prelamin A endoprotease: an enzyme which catalyzes the conversion of farnesylated prelamin A to mature lamin A. FEBS Letters. 1999, 450: 61-65. 10.1016/S0014-5793(99)00482-2.
Hegele RA: Drawing the line in progeria síndrome. Lancet. 2003, 362: 416-417. 10.1016/S0140-6736(03)14097-4.
Young SG, Meta M, Yang SH, Fong LG: Prelamin A Farnesylation and progeroid syndromes. J Biol Chem. 2006, 281: 39741-39745. 10.1074/jbc.R600033200.
Shackleton S, Smallwood DT, Clayton P, Wilson LC, Agarwal AK, Garg A, Trembath RC: Compound heterozygous ZMPSTE24 mutations reduce prelamin A processing and result in a severe progeroid phenotype. J Med Genet. 2005, 42: 36-10.1136/jmg.2004.029751.
D'Apice MR, Tenconi R, Mammi I, Ende van den J, Novelli G: Paternal origin of LMNA mutations in Hutchinson-Gilford progeria. Clin Genet. 2004, 65: 52-54. 10.1111/j..2004.00181.x.
Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, Miner JH, Young SG, Fong LG: Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci USA. 2005, 102: 12873-12878. 10.1073/pnas.0505767102.
Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, Meta M, Bendale P, Gelb MH, Young SG, Fong LG: Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation. Proc Natl Acad Sci USA. 2005, 102: 10291-10296. 10.1073/pnas.0504641102.
Glynn MW, Glover TW: Imcomplete processing of mutant lamin A in Hutchinsn-Gilford progeria leads to nuclear abnomalities, which are reversed by farnesyltransferase inhibition. Hum Mol Gen. 2005, 14: 2959-2969. 10.1093/hmg/ddi326.
Yang SH, Qiao X, Fong LG, Young SG: Treatment with farnesyltransferase inhibitor improves survival in mice with Hutchinson-Gilford Progeria Syndrome Mutation. Biochim Biophys Acta. 2008, 1781: 36-39.
Capell BC, Olive M, Erdos MR, Cao K, Faddah DA, Tavarez UL, Conneely KN, Qu X, San H, ganesh SK, Chen X, Avallone H, Kolodgie FD, Virmani R, Nabel EG, Collins FS: A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Nat Acad Sci USA. 2008, 105: 15902-15907. 10.1073/pnas.0807840105.
Young SG, Fong LG, Michaelis S: Prelamin A, Zmpste24, misshapen cell nuclei, and progeria – new evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res. 2005, 46: 2531-2558. 10.1194/jlr.R500011-JLR200.
Meta M, Yang SH, Bergo MO, Fong LG, Young SG: Protein farnesyltransferase inhibitors and progeria. Trends Mol Med. 2006, 12: 480-487. 10.1016/j.molmed.2006.08.006.
The authors declare that they have no competing interests.
VSFS, RBN and GFG contributed to conception and design, designed the review, carried out the literature research, and manuscript preparation. HDMC contributed to conception and design, carried out the manuscript editing and manuscript review. All authors read and approved the final manuscript. We declare that all figures used in this article were authorized by the corresponding authors of the cited articles, Dr. Stephen G. Young and Dr. Francis S. Collins.
About this article
Cite this article
Coutinho, H.D.M., Falcão-Silva, V.S., Gonçalves, G.F. et al. Molecular ageing in progeroid syndromes: Hutchinson-Gilford progeria syndrome as a model. Immun Ageing 6, 4 (2009). https://doi.org/10.1186/1742-4933-6-4
- Nuclear Envelope
- Farnesyltransferase Inhibitor
- Gene LMNA
- LMNA Mutation